Advanced Chemotherapy Technologies Closes $5.5M Series A Funding

Advanced Chemotherapy Technologies

Advanced Chemotherapy Technologies, Inc., a Raleigh, N.C.-based clinical-stage drug delivery company, closed a $5.5m Series A funding round.

The round was led by Khosla Ventures.

The company intends to use the funds for initial clinical development of its ACT-IOP-003 local chemotherapy system for the treatment of locally advanced non-resectable and borderline resectable pancreatic cancer.

Led by Tony Voiers, CEO, Advanced Chemotherapy Technologies is a clinical-stage company developing novel approaches to local drug delivery. Its lead product is the first-in-class to combine iontophoresis drug delivery with an implantable delivery system to target drug delivery with laser-like precision. Its drug delivery technology was first developed at and licensed from the University of North Carolina at Chapel Hill in conjunction with UNC Lineberger Comprehensive Cancer Center.



Join the discussion